Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Depreciation & Amortization: 2016-2025

Historic Accumulated Depreciation & Amortization for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $2.7 million.

  • Rocket Pharmaceuticals' Accumulated Depreciation & Amortization rose 42.11% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 32.35%. This contributed to the annual value of $7.2 million for FY2024, which is 46.94% up from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Accumulated Depreciation & Amortization is $2.7 million, which was up 8.00% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Accumulated Depreciation & Amortization peaked at $9.1 million during Q4 2022, and registered a low of $1.1 million during Q1 2023.
  • For the 3-year period, Rocket Pharmaceuticals' Accumulated Depreciation & Amortization averaged around $1.8 million, with its median value being $1.8 million (2024).
  • Per our database at Business Quant, Rocket Pharmaceuticals' Accumulated Depreciation & Amortization soared by 200.35% in 2021 and then crashed by 85.00% in 2023.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Accumulated Depreciation & Amortization stood at $5.2 million in 2021, then skyrocketed by 74.10% to $9.1 million in 2022, then slumped by 84.60% to $1.4 million in 2023, then grew by 28.57% to $1.8 million in 2024, then surged by 42.11% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.5 million for Q2 2025, and $2.0 million during Q1 2025.